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Abstract
Background: Spinocerebellar ataxias (SCA) are a group of hereditary neurodegenerative disorders. Prevalence of
SCA subtypes differ worldwide. Autosomal dominant ataxias are the commonest types of inherited ataxias seen in
Sri Lanka. The aim of the study is to determine the genetic etiology of patients with autosomal dominant ataxia in
Sri Lanka and to describe the clinical features of each genetic subtype.
Methods: Thirty four patients with autosomal dominant ataxia were recruited. For every patient the following was
done: recording of clinical details and genotyping for SCA 1, 2, 3, 6, 7, 8, 12, and 17.
Results: Sixty one per cent of the subjects were identified as SCA1. One subject had SCA2, 12 remain unidentified.
Mean age at onset was 34.8 ± 10years for SCA1 and 32.7 ± 9.8 for non SCA1. 76% of SCA1 patients and 50% of non
SCA1 were using walking aids. Quantification of symptoms and signs were similar in the SCA1 and non SCA1
groups. Clinical depression was evidenced in 68.4% of SCA1 and 75% non SCA-1 patients. Mean CAG repeat length
in SCA1 patients was 52.0 ± 3.8, with greater anticipation seen with paternal inheritance.
Conclusion: SCA1 was the predominant subtype and showed similar phenotype to previous reports. However,
disease severity was higher and depression more prevalent in this population than previously described.
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Background
Spinocerebellar ataxias (SCA) are a clinically and genet-
ically heterogeneous group of neurodegenerative disor-
ders [1]. Clinical features include progressive limb and
gait ataxia, loss of coordination, disturbance of speech
and occulomotor control. Patients may also present with
additional non ataxia symptoms such as pyramidal
(hyperreflexia, extensor plantar response, spasticity),
extrapyramidal (myoclonus, rigidity, chorea, dystonia,)
and autonomic dysfunction. With clinical phenotypes
variable and often overlapping, genotyping has emerged
as a more accurate classificatory tool. At present, more
than 30 different SCA subtypes have been genetically de-
fined with 22 subtypes having genetic mutation isolated,
with 12 subtypes being caused by repeat expansion [2].
Wide geographical variation in prevalence of auto-
somal dominant SCA is seen partly due to founder mu-
tations [3]. SCA 1, 2, 3, 6, and 7 caused by trinucleotide
repeats are the most prevalent SCA subtypes worldwide.
SCA1 and 2 are common in Italy, South Africa and
India. SCA 3 is the most prevalent subtype in Portugal,
Germany, Brazil, and China. High frequency of SCA 6 is
reported from Japan, Germany and North American
countries. SCA7 is reported as a common SCA type of
South African families of Black ethnic origin [4]. The
majority of epidemiological studies conducted on the
prevalence of SCA are from Europe. Only a few have fo-
cused on Africa and Asia. In the South Asian region,
most studies originate from India, and show a variation
in SCA prevalence with increased SCA 1 in south India
and SCA 2 in east India [5-9] (Table 1).
Genetic diagnosis of familial disease remains a rela-
tively new field in Sri Lanka. Rare diseases like heredi-
tary ataxia may remain undiagnosed due to acceptance
of the disease as a familial idiosyncrasy. This is
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particularity true if it is characterized by late onset and
slow progression. Knowledge about the frequency, oc-
currence and clinical type of disease is an important
public health care issue, necessary for identification,
follow-up and genetic counseling of patients.
To the best of our knowledge there are no data re-
garding SCA in Sri Lanka, where a population of ap-
proximately 20 million reside. We report the clinical and
genetic results in 34 patients identified with autosomal
dominant ataxia in Sri Lanka. Though not representative
for the whole of Sri Lanka, this study was conducted as
an initial assessment of a cohort of patients for the pres-
ence of autosomal dominant ataxia in Sri Lanka, and to
further characterize the phenotypes and genotypes of
the identified affected subjects.
Methods
This study was conducted at the Human Genetics Unit
(HGU), Faculty of Medicine, University of Colombo,
which is the only center in Sri Lanka providing genetic
diagnostic and counseling services in the government
sector. It receives referrals from all the tertiary care hos-
pitals and other healthcare institutions across Sri Lanka.
The archives of the Human Genetics Unit were accessed
for referrals of dominant ataxia between January 2005 and
December 2011. Of the total 40 patients in the referred
database 22 were contactable and agreed to participate in
the study. A further patient population was identified from
an isolated geographical region following information
from the already included patients. Twelve patients were
recruited from this region.
Inclusion criteria were: Adults aged 18 years and more
with progressive cerebellar ataxia with autosomal dom-
inant inheritance pattern of affected family members
and/or verified molecular diagnosis. Exclusion criteria
were: ataxia with secondary cause or sporadic ataxia.
Thirty-four patients were thus included in the final
evaluation.
Clinical examination
The patients were examined and evaluated by 3 investi-
gators of the project. They were evaluated according to
the standard clinical protocol for ataxia patients
(SPATAX evaluation form )[10], which carries a score of
0 to 7, with 0 = no functional handicap and 7 = confined
to bed. Scale for Assessment and Rating of Ataxia
(SARA), which quantifies ataxia from 0 to 40 and Inven-
tory of Non Ataxia Symptoms (INAS), which is a semi-
quantitative variable of extracerebellar involvement
summed into 16 binary variables [11,12]. Coexistent
depression was assessed using the Patient Health Ques-
tionnaire (PHQ) [13]. Correlations between disease
phenotype and genotype and depression levels were
assessed.
The study protocol was approved by the institutional
ethics committee of the Faculty of Medicine, University
of Colombo, Sri Lanka. All patients gave written in-
formed consent prior to participating in the study.
Molecular analyses
DNA was extracted from peripheral blood leucocytes.
Genetic testing for SCA 1, 2, 3, 6 7, and 8 repeats was
done by multiplex amplification and capillary electro-
phoresis [14,15] These analyses were performed at the
Human Genetics Unit, Faculty of Medicine, University
of Colombo, Sri Lanka. In addition SCA 12 and SCA 17
targeted mutation analyses of trinucleotide repeat re-
gions were performed according to standard earlier pub-
lished protocols at the research diagnostic section of the
Department of Medical Genetics, Oslo University Hos-
pital [16,17].
Statistics
Descriptive statistics were performed using percentages,
means and standard deviations. Comparison of non para-
metric data between groups was done using Chi square
test. Comparison of means was done using the Students’ t
test with significance observed using ANOVA. Correla-
tions were obtained using the Pearson correlation. Binary
and continuous variables were analyzed using logistic
regression and multiple regression analysis respectively.
Statistical significance was set at p < 0.05.
Table 1 Reports of SCA subtypes in the Indian Subcontinent up to 2012
Region Year N SCA subtype
SCA 1 SCA 2 SCA 3 SCA 6 SCA 7
India South [5] 2003 -2006 284 34 (31.8%) 24 (22.4%) 15 (14%) N/A N/A
India – South [6] 2005 236 7.2% N/A N/A N/A N/A
India East ( West Bengal ) [7] 2004 28 2 (14.3%) 4 (28.6%) 5 (35.7%) 0 0
India Mostly North [8] 2000 42 3 (7.1%) 10 (23.8%) 2 (4.8%) 0 0
India East ( West Bengal ) [9] 1997 – 1999 57 6 (10.5%) 10 (17.5%) 4 (7.0%) 1 (1.8%) 0
N = patient number included in the study.
N/A = these subtypes were not investigated in the studies.
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Results
A total of 34 patients were recruited from 27 families with
autosomal dominant hereditary ataxia. Spinocerebellar
ataxia type 1 (SCA 1) was found in 14 families. SCA 2 was
found in 1 while no genetic diagnosis could be established
in the remaining 12. SCA type 3, 6, 7, 8 12 or 17 muta-
tions were excluded. A SCA1 genotype frequency of 51.8%
(14/27) was thus established in the cohort making it the
predominantly observed SCA subtype.
Mean age of onset of disease was similar in SCA1 and
non SCA1 patients; duration of disease was longer in the
non SCA1 patients. Patient disability and SARA scores
were higher in the SCA1 group (Table 2). The mean
SARA score of SCA1 patients had positive correlation
with disease duration (R2 = 0.2, p = 0.2) and negative cor-
relation with the age at onset (R2 = 0.6, p < 0.05). The most
prevalent non-ataxia signs at examination seen in SCA1
and non SCA1 patients were hyperreflexia (76.2% and
67%) and spasticity (81% and 50%). However among the
non- ataxia symptoms non SCA1 patients had more sen-
sory symptoms such as reduced vibration sense (76.2% vs
50% and 28.6% vs 41.7%). Hyperreflexia, spasticity, urinary
dysfunction and cognitive decline increased significantly
with age in the SCA1 patient group alone.
The PHQ was answered by 19 (90.5%) patients with
SCA1 and 100% non- SCA1 patients. There was a high,
clinically relevant level of depression in both groups
(68.4% and 75%). Sleep disturbance was cited as the
most significant symptom in both patient groups.
The mean CAG repeat length in SCA 1 patients was
52.0 ± 3.8 (47–59). Anticipation was present in the patient
group with a significant reduction in the age of onset of
patients compared to their parents (p < 0.005). There was
also an inverse correlation between the age of onset and
CAG repeat length in the expanded allele. Most subjects
had inherited their mutation paternally (71.4%) with a sig-
nificant difference in the degree of anticipation seen
according to the transmitting parent (Table 3).
Of the total 21 SCA1 patients, 15 were from a single
geographical location in the southern province. A large
pedigree in the study was from this region (Figure 1). It
accounts for 4 of the 15 patients recruited into the
study. (Patient number 15, 16, 19 and 49).
Discussion
This is the first study in clinical genetics of dominant
ataxia conducted in Sri Lanka. Interestingly, SCA 1 was
the most frequent occurring type of SCA identified in
the study, accounting for 61.7% of all identified SCA.
Only one SCA 2 family was found, but no SCA3, 6, 7, 8
12 or 17. Moreover, the clinical findings suggest a more
severe disease course in the SCA 1 patients compared
with previous reports. Last but not least this study re-
vealed the presence of isolated non diagnosed patients’
groups in the country.
Study population
The patients recruited were predominantly from the
south and west of the country which accounts for ap-
proximately 43% of the total population [18]. This re-
cruitment bias makes it impossible to give a reliable
epidemiological data for the whole country. However
when comparing the SCA subtype found in Sri Lanka
with Indian populations (Table 1), the similarities are
more with South Indian data. The geographical and gen-
etic proximity with South India with migratory phenom-
ena may have influenced the epidemiology of SCA in
Sri Lanka [5,19]. Further studies are needed to confirm
the true epidemiological spread of SCA subtypes and
haplotype analysis to investigate the presence of founder
mutations.
Apart from the 12 patients recruited from the South
all other patients were recruited based on recall of ar-
chives. This may also have caused a recruitment bias by
excluding patients from remote regions and patients
with SCA phenotypes that include non-ataxia symptoms
such as cognitive impairment, emphasizing the need a
further epidemiological study.
Table 2 Clinical characteristics of patients with SCA1, SCA2 and unknown genetic etiology
Genetic Diagnosis N Mean age
symptom
onset
(years)
Disability
level*
SARA** INAS*** Clinically
relevant
depression
*****
(0–40) (0–16)
SCA1 21 34.8 ± 10 4 ± 2 18.8 ± 9.7 3.6 ± 2.4 68.4%
SCA2 1 34.0 6 26 6 100%
Unknown genetic etiology 12 32.7 ± 9.8 3 ± 2.7 13.7 ± 7.1 3.8 ± 2.1 75%
N = patient number included in the study.
*Disability level was quantified using the SPATAX score. (0 = No functional handicap, 1 = No functional handicap but signs at examination, 2 =mild unable to run,
walking unlimited, 3 =moderate unable to run, limited walking without aid, 4 = severe walking with one stick, 5 = walking with two sticks, 6 = unable to walk
requiring wheelchair, 7 = confined to bed).
**SARA = Scale of Assessment and Rating of Ataxia.
***INAS = Inventory of Non ataxia Symptoms.
****Clinically relevant depression as percentage of total subtype patient population - assessed using the Patient Health Questionnaire 9 (PHQ9).
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Clinical phenotype
Clinical findings in the SCA1 patients are in accordance
with most published series. Anticipation is present with
a significantly higher contribution of mutant alleles pa-
ternally transmitted in the study population. This is in
accordance with the previous findings that in SCA 1,
CAG repeats are more unstable and larger in size when
transmitted paternally [20].
An increase in disability level with duration of disease
was present as expected; however the level of disability
was greater than compared to previous reports. Al-
though the disease duration was shorter in our study
than in EUROSCA (7.4 ± 3.1vs 9.5 ± 5.5) the mean SARA
score of 18.8 ± 9.7 was higher (15.6 ± 9.1) [21]. This may
be related to the relatively higher CAG repeat length in
the study population (Tables 2 and 3), resulting in a
Table 3 Familial inheritance pattern and genetic characteristics of SCA1 patients
N SCA1 = 21
Father Mother
Parental transmission – Father / Mother 15 (71.4%) 6 (28.6%)
Age difference between transmitting parent and child – (Mean ± SD) 12.6 ± 5.4 6.8 ± 2.4
CAG repeat number - Mean ± SD (range) 52.0 ± 3.8 (47–59)
N = Number of patients.
------
Unaffected Affected status unknown Affected
Male Female Gender anonymised to retain 
confidentiality of the family
Proband (Patient recruited into the study and 
with a genetic diagnosis of SCA1 established)
55 patient is represented twice and shown by (---) to 
connect him by consanguineous marriage to 33
Figure 1 Pedigree of a family with SCA 1 from the Southern province of Sri Lanka.
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rapidly progressive severe phenotype. In addition a
poor level of para-clinical supportive services such as
physiotherapy for the neurodegenerative disease might
also be contributing to disability.
INAS count showed increased pyramidal signs which
were similar to previous reports on SCA1. However the
mean INAS score was lower than previously reported
(3.6 ± 2.4 vs 5.0 ± 2.3) indicating a phenotype with rela-
tively less extracerebellar signs [22]. This may of course
be a bias due to the sample’s small size.
There were a surprisingly higher number of patients
with depression compared to previous reports that used
the same scoring system in SCA patients (68.4% vs
24.5%) [13]. Between the two studies the proportion of
patients with no depression, mild, moderate and severe
depression was inversely related, with high patient num-
bers with severe depression in this study population.
There was significantly less social support, financial secur-
ity and increased disability due to lack of physiotherapy in
our patients’ cohort. Identification and treatment of de-
pression was also nonexistent. In chronic neurodegenera-
tive disease physiotherapy and occupational therapy have
been shown not only to slow the progression of neuro-
logical deterioration but also to have positive effects on
the mental health status of patients as does medical inter-
ventions for depression [23,24]. This highlights the need
for supportive care in the hereditary ataxias.
Familial aggregation of mutation
A familial aggregation of SCA1 was found in the Southern
region of Sri Lanka. The presence of a founder mutation
could account for this, and further studies are ongoing to
verify this hypothesis. Surprisingly consanguinity was found
in SCA 1 families. It appears to be induced by the social
conventions [25]. It is part influenced by the inter marriage
of individuals within the same caste and by the need to
limit the burden of social stigma attached to the disease on
the individual by marriage into a similarly affected family.
The need of genetic services and health information and
education to these regions is clearly emphasized by these
findings. The researchers travelled to the homes of the pa-
tients in this village for examination and investigations.
Until recruitment to the study they had not been seen by a
medical professional. This may indicate that further pockets
of isolated patients’ populations are present within the is-
land. The single SCA2 patient identified was the only pa-
tient from the central region. The learning’s of this study
are that other patients with SCA2 may be present in this
region and should be specifically looked for by health care
workers in order to provide a genetic diagnosis.
Conclusion
This is the first report on autosomal dominant in
Sri Lanka, with mostly SCA1 patients in the cohort of
patients studied. There are, however, indications that
more affected subjects are present in hidden pockets,
isolated and undetected. Further studies are needed to
identify the epidemiological spread of patients and con-
firm founder mutations. High levels of clinically signifi-
cant depression indicate that health care services need
to focus in this area to increase the quality of life in
affected subjects.
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